The role of the urologist in adjuvant chemotherapy trials for prostate cancer.
The urologist is ideally positioned to identify patients at high risk for relapse after radical prostatectomy. Several models have been proposed to help the urologist identify which patients are at risk and who should be considered for adjuvant therapy after radical prostatectomy. The appropriate initial trial design considered for this group of patients should be a randomized two-arm trial, without androgen deprivation, to assess more quickly the efficacy of selected agents.
Presti
J C
JC
Department of Urology, University of California, San Francisco, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D008297:Male; D018579:Patient Selection; D010819:Physician's Role; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014572:Urology / Q000379:methods*
D000970:Antineoplastic Agents